ALT On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt

altimmune inc (ALT) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALTIMMUNE INC (ALT)
\

altimmune inc (ALT) Related Businessweek News

No Related Businessweek News Found

altimmune inc (ALT) Details

Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that is in Phase II clinical trials; HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials; and NasoShield, a vaccine for the prevention of anthrax disease following inhalation of bacterial spores that is in Phase I clinical trials. Its preclinical stage products include SparVax-L, a recombinant protein-based anthrax vaccine; and Oncosyn, an immunotherapeutic for treating cancer. The company also develops veterinary product candidates. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.

27 Employees
Last Reported Date: 04/1/19

altimmune inc (ALT) Top Compensated Officers

President, CEO & Director
Total Annual Compensation: $143.6K
Executive Chairman
Total Annual Compensation: $165.4K
CFO & Principal Accounting Officer
Total Annual Compensation: $216.0K
Chief Medical Officer
Total Annual Compensation: $529.6K
Compensation as of Fiscal Year 2018.
altimmune inc
Altimmune, Inc. to Report Q1, 2019 Results on May 15, 2019

Altimmune, Inc. announced that they will report Q1, 2019 results at 9:00 AM, Eastern Standard Time on May 15, 2019

Altimmune, Inc., Q1 2019 Earnings Call, May 15, 2019

Altimmune, Inc., Q1 2019 Earnings Call, May 15, 2019

Altimmune To Seek Acquisitions

Altimmune, Inc. (NasdaqGM:ALT) will look for acquisitions. Altimmune intends to use the net proceeds from the sale of the $250,000,000 offered securities for general corporate purposes, including repayment or redemption of outstanding debt or preferred stock, the possible acquisition of related businesses or assets thereof, and working capital needs.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

ALT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALT.
View Industry Companies
 

Industry Analysis

ALT

Industry Average

Valuation ALT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.2x
Price/Book 0.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ALTIMMUNE INC, please visit www.altimmune.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.